Join
Live feed
·
PRReleasevia Quantisnow
Pasithea Therapeutics Corp. logo

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

ByQuantisnow·Wall Street's wire, on your screen.
KTTA· Pasithea Therapeutics Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KTTA (Pasithea Therapeutics Corp.) and more on Quantisnow.